1stOncology™: Cancer Intelligence Service – Page 13754 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

TRACON Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

On May 30, 2019 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd., wet age‐related macular degeneration, reported that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the Jefferies 2019 Healthcare Conference at 2:30 pm EDT on Friday, June 7, 2019, in New York, NY (Press release, Tracon Pharmaceuticals, MAY 30, 2019, View Source [SID1234536702]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentations" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

PIERIS PHARMACEUTICALS TO PRESENT AT THE JEFFERIES 2019 HEALTHCARE CONFERENCE

On May 30, 2019 Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory, cancer and other diseases, reported that Stephen Yoder, President and Chief Executive Officer of Pieris Pharmaceuticals, Inc., will present at the Jefferies 2019 Healthcare Conference in New York, New York on Thursday, June 6, 2019 at 3:30 PM (EDT) (Press release, Pieris Pharmaceuticals, MAY 30, 2019, View Source [SID1234536701]). A webcast of the company’s presentation will be available at this link.

Immunocore to present at the Jefferies 2019 Global Healthcare Conference in New York

On May 30, 2019 Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, reported that Bahija Jallal, Chief Executive Officer, and David Berman, Head of Research and Development, will be presenting at the Jefferies 2019 Global Healthcare Conference in New York on Friday 7 June at 2:30pm ET (Press release, Immunocore, MAY 30, 2019, View Source [SID1234536700]).

For meeting requests, please contact Julian Hirst at [email protected].

argenx to Present at Upcoming Investor Conferences

On May 30, 2019 argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported that management will present at two upcoming investor conferences in June (Press release, argenx, MAY 30, 2019, View Source [SID1234536699]):

Jefferies 2019 Global Healthcare Conference. Company presentation on Thursday, June 6, 2019 at 10:30 a.m. ET in New York.

Goldman Sachs 40th Annual Global Healthcare Conference. Fireside chat on Wednesday, June 12, 2019 at 11:20 a.m. PT in Palos Verdes.

Live webcasts of each presentation will be available on the Company’s website at www.argenx.com. Replays of the webcasts will be available for 90 days following each presentation.

XBiotech Announces Public Offering of Common Shares

On May 30, 2019 XBiotech Inc. (NASDAQ: XBIT) reported that it has commenced an underwritten public offering of common shares, subject to market and other conditions (Press release, XBiotech, MAY 30, 2019, View Source [SID1234536697]). XBiotech intends to grant the underwriter in the offering a 30-day option to purchase additional common shares.

Piper Jaffray is acting as the sole underwriter in the offering.

Net proceeds of the offering will be used primarily to advance bermekimab Phase 2 clinical trials in Hidradenitis Suppurativa and Atopic Dermatitis and for general corporate and working capital purposes. Completion of the offering is subject to customary closing conditions.

The common shares are being offered pursuant to an effective shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. The prospectus supplement and accompanying prospectus relating to the offering contain important information relating to the XBiotech common shares. The prospectus supplement will be filed with the SEC and will be available on the SEC’s website at View Source, or may be obtained, when available, by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by email at [email protected], or by phone at (800) 747-3924. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering may only be made by means of a prospectus supplement and related base prospectus.